Contribute Try STAT+ Today

Good morning, everyone, and nice to see you again. We have returned, so to speak, from our week-long holiday, which mostly involved family and household matters, as one might imagine these days. Nonetheless, we are somewhat invigorated and hope you feel the same after the weekend respite. Of course, those familiar weekday routines have returned. To cope, yes, we are brewing a cup or three of stimulation. Maple bourbon is the choice for now. Please feel free to join us. Meanwhile, here is the latest menu of interesting items to help you along. Hope your day goes reasonably well and, as always, do stay in touch. …

Moderna (MRNA) received an additional $472 million from the U.S. Biomedical Advanced Research and Development Authority to support development of its Covid-19 vaccine, Reuters notes. The additional funding will support late-stage clinical development including an expanded Phase 3 study that is now under way. In April, Moderna had received $483 million from BARDA, when the experimental vaccine was in an early-stage trial conducted by the U.S. National Institutes of Health.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • From the LiveMint item – may I observe that it does seem the Indian authorities are more realistic than at least some in the US Congress? – ““We understand that the APIs (active pharmaceutical ingredients) cannot be 100% produced domestically. Companies will have to import some raw materials. So, we will allow them a 30% import limit under the scheme,” {They understand there is no magic solution.)

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy